202 related articles for article (PubMed ID: 35372029)
21. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
22. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer
Zhang Y; Huang Y; Yin Y; Fan Y; Sun W; Zhao X; Tucker K; Staley A; Paraghamian S; Hawkins G; Prabhu V; Allen JE; Zhou C; Bae-Jump V
Front Oncol; 2020; 10():577141. PubMed ID: 33194693
[TBL] [Abstract][Full Text] [Related]
23. Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese
Han J; Wysham WZ; Zhong Y; Guo H; Zhang L; Malloy KM; Dickens HK; Huh G; Lee D; Makowski L; Zhou C; Bae-Jump VL
Oncotarget; 2017 Dec; 8(67):110965-110982. PubMed ID: 29340030
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
Jin ZZ; Wang W; Fang DL; Jin YJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
[TBL] [Abstract][Full Text] [Related]
25. Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity.
Jin Z; Jin Y
Turk J Gastroenterol; 2023 Mar; 34(3):211-220. PubMed ID: 36511604
[TBL] [Abstract][Full Text] [Related]
26. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
28. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
Fennell EMJ; Aponte-Collazo LJ; Pathmasiri W; Rushing BR; Barker NK; Partridge MC; Li YY; White CA; Greer YE; Herring LE; Lipkowitz S; Sumner SCJ; Iwanowicz EJ; Graves LM
Front Pharmacol; 2023; 14():1136317. PubMed ID: 37063293
[TBL] [Abstract][Full Text] [Related]
29. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
30. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.
Lim B; Peterson CB; Davis A; Cho E; Pearson T; Liu H; Hwang M; Ueno NT; Lee J
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680527
[TBL] [Abstract][Full Text] [Related]
31. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
32. Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.
Jackson AL; Sun W; Kilgore J; Guo H; Fang Z; Yin Y; Jones HM; Gilliam TP; Zhou C; Bae-Jump VL
Oncotarget; 2017 Nov; 8(59):100113-100127. PubMed ID: 29245964
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.
Huang Y; Fan Y; Zhao Z; Zhang X; Tucker K; Staley A; Suo H; Sun W; Shen X; Deng B; Pierce SR; West L; Yin Y; Emanuele MJ; Zhou C; Bae-Jump V
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569750
[TBL] [Abstract][Full Text] [Related]
34. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
[TBL] [Abstract][Full Text] [Related]
35. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
36. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
37. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
Zhang J; Luo B; Sui J; Qiu Z; Huang J; Yang T; Luo Y
Biochem Pharmacol; 2022 Oct; 204():115232. PubMed ID: 36030831
[TBL] [Abstract][Full Text] [Related]
38. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
39. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
[TBL] [Abstract][Full Text] [Related]
40. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
Ni X; Zhang X; Hu CH; Langridge T; Tarapore RS; Allen JE; Oster W; Duvic M
Oncotarget; 2017 Sep; 8(37):61761-61776. PubMed ID: 28977902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]